Background
Medulloblastoma is the most common malignant pediatric brain tumor and, unfortunately, nearly one-third of affected children ultimately die of the disease despite aggressive therapy. High-risk medulloblastoma and recurrent tumors portend an even poorer prognosis. To improve patient outcomes, our primary goal is to improve methods to noninvasively detect tumor progression or relapse at early stages that will likely offer therapeutic opportunities or alter treatment strategies.
